

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:

BAELL et al.

Serial No.: Not yet assigned

Filed: Herewith

Atty. File No.: 4102-5-1

For: "Fc RECEPTOR MODULATORS
AND USES THEREOF"

Box PATENT APPLICATION
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to the initial review of the above-identified patent application by the Examiner,
please enter the following Preliminary Amendment. Although Applicants do not believe that any
fees are due based upon the filing of this Preliminary Amendment, please charge any such fees to
Deposit Account 19-1970.

Please amend the above-identified patent application as follows:

IN THE SPECIFICATION:

Please replace the paragraph beginning at page 1, line 3 of the specification with the
following paragraph:

This application is a continuation of application number 09/393,598 filed 10 September
1999.

) Group Art Unit:

) Examiner:

) FIRST PRELIMINARY AMENDMENT

) "EXPRESS MAIL" MAILING LABEL NUMBER: EK 778148286 US
) DATE OF DEPOSIT: NOVEMBER 26, 2001

) I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
) DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
) "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE
) UNDER 37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE AND IS
) ADDRESSED TO THE U.S. PATENT AND TRADEMARK OFFICE,
) ARLINGTON, VA 22202

) TYPED OR PRINTED NAME: Christine Jacquet

) SIGNATURE: Christine Jacquet


IN THE CLAIMS:

Please cancel Claims 1-107 without prejudice to, or disclaimer of, the subject matter contained therein.

Please add new claims 108-150 as follows:

108. (New) A pharmaceutical composition comprising:

a compound having the formula



or salts thereof,

wherein

each of W^1 and W^2 is independently CO_2R^3 , $\text{C}(=\text{NH})\text{NH}(\text{OH})$, $\text{PO}(\text{OR}^3)_2$ or $\text{C}(=\text{O})\text{CF}_3$;


each of R^1 and R^2 is a bond, CH_2 or $\text{C}_1\text{-C}_6$ alkylene;

each of Ar^1 and Ar^2 is independently $\text{C}_5\text{-C}_{20}$ aryl or $\text{C}_1\text{-C}_{20}$ heteroaryl;


L is a linker comprising from 1 to about 20 atoms; and,

R^3 is hydrogen or $\text{C}_1\text{-C}_6$ alkyl.


109. (New) The composition of Claim 108, wherein said compound is of the formula:



110. (New) The composition of Claim 108, wherein said compound is of the formula:




111. (New) The composition of Claim 108, wherein said compound is of the formula:




112. (New) The composition of Claim 108, wherein L is selected from the group consisting of C₁-C₂₀ alkoxy, C₆-C₂₀ aryl and C₁-C₆ heteroaryl.

113. (New) The composition of Claim 112, wherein L is -CH₂O-.

114. (New) The composition of Claim 112, wherein L is a moiety of the formula:




115. (New) The composition of Claim 112, wherein L is a moiety of the formula:




wherein each of R^4 and R^5 is independently H, C_1 - C_6 alkyl, C_8 - C_{10} aralkyl or a protecting group.


116. (New) The composition of Claim 108, wherein the compound is of the formula:




117. (New) The composition of Claim 108, wherein the compound is of the formula:




118. (New) The composition of Claim 108, wherein the compound is of the formula:




119. (New) The composition of Claim 108, wherein the compound is of the formula:




120. (New) The composition of Claim 108, wherein the compound is of the formula:



121. (New) The composition of Claim 108, wherein the compound is of the formula:



122. (New) A method for inhibiting Fc receptor binding of immunoglobulin in a patient comprising administering to such patient a pharmaceutically effective amount of a compound of the formula:



or salts thereof,

wherein

each of W^1 and W^2 is independently CO_2R^3 , $\text{C}(=\text{NH})\text{NH}(\text{OH})$, $\text{PO}(\text{OR}^3)_2$ or $\text{C}(=\text{O})\text{CF}_3$;

each of R^1 and R^2 is a bond, CH_2 or $\text{C}_1\text{-C}_6$ alkylene;

each of Ar^1 and Ar^2 is independently $\text{C}_5\text{-C}_{20}$ aryl or $\text{C}_1\text{-C}_{20}$ heteroaryl;

L is a linker comprising from 1 to about 20 atoms; and,

R^3 is hydrogen or $\text{C}_1\text{-C}_6$ alkyl.

123. (New) The method of Claim 122, wherein said Fc receptor is selected from the group consisting of $\text{Fc}\alpha\text{R}$, $\text{Fc}\epsilon\text{R}$, $\text{Fc}\gamma\text{R}$ and mixtures thereof.


124. (New) The method of Claim 122, wherein said Fc receptor is selected from the group consisting of $\text{Fc}\gamma\text{RIIa}$, $\text{Fc}\gamma\text{RIIb}$, $\text{Fc}\gamma\text{RIIc}$ and mixtures thereof.

125. (New) The method of Claim 122, wherein said method reduces IgG-mediated tissue damage in said patient.


126. (New) The method of Claim 122, wherein said method reduces inflammation in said patient.
127. (New) The method of Claim 122, wherein said method is used to treat an autoimmune disease.
128. (New) The method of Claim 122, wherein said method is used to treat a disease where aggregates of antibodies are produced or where immune complexes are produced by contact of antibody with intrinsic or extrinsic antigen.
129. (New) The method of Claim 128, wherein said disease is selected from the group consisting of immune complex diseases, autoimmune diseases, infectious diseases and vasculitities.
130. (New) The method of Claim 129, wherein said autoimmune disease is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, immune thrombocytopenia, neutropenia, and hemolytic anaemias.
131. (New) The method of Claim 129, wherein said vasculitities is selected from the group consisting of polyarteritis nodosa, and systemic vasculitis.
132. (New) The method of Claim 122, wherein said method is used to treat xenograft rejection.
133. (New) The method of Claim 129, wherein said infectious disease is selected from the group consisting of Dengue virus-dengue hemorrhagic fever and measles virus infection.
134. (New) The method of Claim 122, wherein said method reduces IgE-mediated response in said patient.

135. (New) The method of Claim 122, wherein said compound is selected from the group consisting of folic acid, 4-methyl benzoic acid, 3-methyl benzoic acid and a nucleoside or analogs thereof.


136. (New) The method of Claim 122, wherein said compound is of the formula:



137. (New) The method of Claim 122, wherein said compound is of the formula:



138. (New) The method of Claim 122, wherein said compound is of the formula:




139. (New) The method of Claim 138, wherein W^1 and W^2 are CO_2H .

140. (New) The method of Claim 138, wherein R^1 and R^2 are a bond.


141. (New) The method of Claim 140, wherein L is selected from the group consisting of C_1 - C_{20} alkoxy, C_6 - C_{20} aryl and C_1 - C_6 heteroaryl.

142. (New) The method of Claim 140, wherein L is $-\text{CH}_2\text{O}-$.

143. (New) The method of Claim 140, wherein L is a moiety of the formula:




144. (New) The method of Claim 140, wherein L is a moiety of the formula:




wherein each of R^4 and R^5 is independently H, C_1 - C_6 alkyl, C_8 - C_{10} aralkyl or a protecting group.


145. (New) The method of Claim 140, wherein the compound is of the formula:




146. (New) The method of Claim 140, wherein the compound is of the formula:




147. (New) The method of Claim 140, wherein the compound is of the formula:




148. (New) The method of Claim 140, wherein the compound is of the formula:



149. (New) The method of Claim 140, wherein the compound is of the formula:



150. (New) The method of Claim 140, wherein the compound is of the formula:



REMARKS

Claims 1-107 from the application have been cancelled without intending to abandon or to dedicate to the public any patentable subject matter. Accordingly, following entry of the foregoing amendments, new Claims 108- 150 will be pending.

All pending claims are believed to be in condition for allowance. In the event that a telephone conversation would further prosecution and/or expedite allowance, the Examiner is invited to contact the undersigned.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: Robert D. Traver

Robert D. Traver

Registration No. 47,999

1560 Broadway, Suite 1200

Denver, Colorado 80202-5141

(303) 863-9700

Date: 26 Nov. 2001